Jun 14,2022

Pierian and Syapse Collaborate with Health Systems, Leveraging Data to Power Precision Oncology

Pierian®, a global leader in advanced clinical genomics technology and services, announced with Syapse®, a leading real-world evidence company, a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida. The collaboration combines Pierian’s leading-edge clinical genomics workflow, and precision medicine services with Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer. Pierian and Syapse will collaborate on optimizing AdventHealth’s internal genomic testing capabilities for all patients who may benefit to improve the actionable insights gathered from test orders and genomic results allowing a deeper understanding of the relationship between these insights and real patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#cdx

View Analyst & Ambassador Comments
Go to original news
Sep 17,2022

Science 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Science 37 Holdings, Inc., the Agile Clinical Trial Operating System™, and Syapse, a leading real-world evidence company, today announced a partnership to deploy proprietary real-world data intelligence and analytics that will help identify suitable patients for oncology clinical trials—ultimately speeding up the enrollment process. Study sponsors are increasingly looking outside of traditional academic sites to source specific patient populations, but without the data to pinpoint patients’ locations, recruitment can be extremely challenging. To facilitate enrollment and reduce patient burden, oncology research executives have begun to rely more on agile (hybrid) and fully decentralized models. The partnership between the companies will enable the Oncology patients and clinical research sponsors to benefit from Syapse’s real-world data intelligence and Science 37’s agile trial operating system, to help accelerate the identification and participation of eligible participants.

COLLABORATION PARTNERSHIP

#product & service

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 05,2022

Illumina, Syapse Partner on Study of Comprehensive Genomic Profiling in Advanced Cancer

Syapse said on Tuesday that it has partnered with Illumina to assess uptake and actionability of comprehensive genomic profiling in the community oncology health system setting. The firms will evaluate single-gene, small panel, and comprehensive genomic profiling tests in advanced cancer patients. A focus of the study, which will use data from the Syapse Learning Health Network, the firm's data aggregation platform, will be trends in testing approaches over time and actionability of results. Syapse will conduct the analysis with input from Illumina. Financial and other terms of the deal were not disclosed. Upon completion of the analysis, the firms hope to present their results at a conference and publish them in a peer-reviewed journal, Syapse said.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 22,2020

BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER

Bayer and Veracyte today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit from biomarker-driven therapies.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#cdx

View Analyst & Ambassador Comments
Go to original news
Jan 08,2020

VERACYTE ANNOUNCES BIOPHARMACEUTICAL COLLABORATION WITH ACERTA PHARMA

Veracyte today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of AstraZeneca (LSE/STO/NYSE: AZN), to provide genomic information that will support the biopharmaceutical company’s development of oncology therapeutics. Financial and other terms of the collaboration were not disclosed. The agreement marks Veracyte’s first biopharmaceutical partnership since the company announced its acquisition of the exclusive diagnostics rights to the NanoString nCounter® platform and genomic tests in breast cancer and lymphoma on December 3, 2019. That transaction positions Veracyte to expand globally using a distributed platform and comprehensive menu of advanced genomic tests.

COLLABORATION PARTNERSHIP

#r&d

#platform

#cdx

View Analyst & Ambassador Comments
Go to original news
Dec 15,2020

VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON

Veracyte, Inc.today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.

COLLABORATION PARTNERSHIP

#r&d

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 27,2017

AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials. ORIEN Avatar is a collaboration between the 15 leading U.S. cancer hospitals that comprise ORIEN, leading pharmaceutical companies and M2Gen, which manages the program. AbbVie is the fourth pharmaceutical company to participate in the Avatar Program. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 09,2021

M2GEN Announces Collaboration with Microsoft to Advance Bioinformatics Solutions for Oncology

M2GEN today announced it is partnering with Microsoft to advance and scale its unique data-driven solutions for the discovery, research and development of new oncology therapies. Since 2014, M2GEN has collected a dataset comprised of tumor and germline genomic data matched with longitudinal, lifetime-consented clinical data from over 300,000 patients. In that time, M2GEN has transformed this dataset into a vital tool that frictionlessly delivers complex oncology data and analytics solutions to researchers in pharmaceuticals, biotechnology, and academia, leading to breakthroughs in oncology science that can improve cancer patient care. M2GEN will collaborate with Microsoft to quickly and meaningfully enhance this tool into a scaled platform that leverages Azure Synapse Analytics with Microsoft Azure Healthcare APIs to enable broad and deep clinico-genomic analysis capabilities and services. The platform will be built on the foundation of Azure Data Lake Storage Gen2 and Azure Purview, the unified data governance solution. 

COLLABORATION PARTNERSHIP

#product & service

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 15,2016

Takeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health Informatics

Takeda Pharmaceutical Company Limited and M2Gen, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program. The data provided through M2Gen’s ORIEN Avatar Research Program has the potential to enable ORIEN cancer centers to more rapidly find and enroll patients with specific biomarkers into Takeda clinical studies, among others.

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 18,2016

PatientsLikeMe and M2Gen Announce Partnership

PatientsLikeMe® and M2Gen® have announced partnership to give patients and researchers a more complete picture of patients’ experiences with cancer treatments and to shed new light on the factors that may affect outcomes and quality of life. The partnership aims to advance cancer research by combining real-world, patient-reported outcomes shared by members of PatientsLikeMe with the molecular and clinical data shared by patients enrolled in the Total Cancer Care® program at Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center. The combined dataset will give researchers a broader, longitudinal view of the many factors that affect patient outcomes. The collaboration’s initial study is expected to kick off within the next several months and to focus on lung cancer. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY